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Abstract  82 
 83 
Epilepsy is a frequent feature of neurodevelopmental disorders (NDD) but little is known 84 
about genetic differences between NDD with and without epilepsy. We analyzed de novo 85 
variants (DNV) in 6753 parent-offspring trios ascertained for different NDD. In the subset of 86 
1942 individuals with NDD with epilepsy, we identified 33 genes with a significant excess of 87 
DNV, of which SNAP25 and GABRB2 had previously only limited evidence for disease 88 
association. Joint analysis of all individuals with NDD also implicated CACNA1E as a novel 89 
disease gene. Comparing NDD with and without epilepsy, we found missense DNV, DNV in 90 
specific genes, age of recruitment and severity of intellectual disability to be associated with 91 
epilepsy. We further demonstrate to what extent our results impact current genetic testing as 92 
well as treatment, emphasizing the benefit of accurate genetic diagnosis in NDD with epilepsy. 93 
 94 
  95 
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Introduction 96 
 97 
Epilepsies, defined as recurrent, unprovoked seizures, affect about 50 million people 98 
worldwide (www.who.int, 03/2017). A significant subset of severe and intractable epilepsies 99 
starts in infancy and childhood and poses a major clinical burden to patients, families, and 100 
society1. Early onset epilepsies are often comorbid with neurodevelopmental disorders (NDD), 101 
such as developmental delay, intellectual disability and autism spectrum disorders (DD, ID, 102 
ASD)2-4, while up to 26% of individuals with NDD have epilepsy, depending on the severity of 103 
intellectual impairment4-6. Several genes have been implicated in both NDD and epilepsy 104 
disorders7,8. The epileptic encephalopathies (EE) comprise a heterogeneous group of epilepsy 105 
syndromes characterized by frequent and intractable seizures that are thought to contribute to 106 
developmental regression3,9. Phenotypic categorisation of clinically-recognizable EE 107 
syndromes enabled identification of several associated genes1,2,10. However, the phenotypic 108 
spectrum of these disease genes was broader than expected11,12, ranging from EE (e.g. SCN1A13, 109 
KCNQ214) to unspecific NDD with or without epilepsy (e.g. SCN2A15, STXBP116). While 110 
clinically distinguishable entities exist, many patients with NDD and epilepsy are not easily 111 
classified into EE syndromes1,12. Consequently, EE is often used synonymously with NDD 112 
with epilepsy17. Targeted sequencing of disease-specific gene panels is commonly used in 113 
diagnostics of epilepsies12,18,19. However, epilepsy gene panel designs of diagnostic laboratories 114 
differ substantially in gene content19.  115 
 Application of a mutational model18 to detect enrichment for de novo variants (DNV) 116 
has proven to be a powerful approach for identification of disease-associated genes in 117 
neurodevelopmental disorders including ID, congenital heart disease, schizophrenia and 118 
ASD20-23. For EE, the currently largest exome-wide DNV burden study comprised 356 parent-119 
offspring trios of two classic EE syndromes (infantile/epileptic spasms, IS and Lennox-Gastaut 120 
syndrome, LGS) and revealed seven genes at exome-wide significance24. To identify genes that 121 
are significantly associated with NDD with epilepsy, we analysed 6753 parent-offspring trios 122 
of NDD, focusing on 1942 cases with epilepsy including 529 individuals with epileptic 123 
encephalopathy. We compared rates of DNV between EE, NDD with unspecified epilepsies 124 
and NDD without epilepsy to identify genetic differences between these phenotypic groups. 125 
We further investigated the potential impact of our findings on the design of genetic testing 126 
approaches and assessed the extent of therapeutically relevant diagnoses.    127 
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Results 128 
 129 
Description of dataset 130 
We analysed DNV in parent-offspring trios of eight published7,20,23-27, one partly published28 131 
and three unpublished cohorts of in total 6753 individuals with NDD stratifying for the 1942 132 
cases with epilepsy (description of cohorts in Supplementary Table 1 and Online Methods, 133 
DNV in Supplementary Table 2). These 1942 patients were ascertained for either EE or NDD 134 
with unspecified epilepsy (DD21, ASD11 with ID and ID20). We define those two phenotype 135 
groups as NDDEE (n = 529) and NDDuE (n = 1413), respectively (visualization Supplementary 136 
Figure S1). We later compared DNV in NDD with epilepsy (NDDEE+uE) to DNV in NDD 137 
without epilepsy (NDDwoE, n = 4811). For genotype-phenotype comparisons, we restricted our 138 
analysis to regions that were adequately captured across different capture solutions (see 139 
Online Methods and Supplementary Figure S2). For ASD data from the Simon Simplex 140 
Consortium29, we included only individuals with IQ < 70 (defined as ID) as different studies 141 
have found DNV only associated with low-IQ ASD6,30. Individuals with NDDEE were 142 
diagnosed with following specific syndromes: IS (n = 243), LGS (n = 145), electrical status 143 
epilepticus in sleep (ESES, n = 42), myoclonic-atonic epilepsy (MAE, n = 39), Dravet 144 
syndrome (DS, n = 16), unspecified EE (n = 44). Six of eight NDD cohorts (n = 6037) 145 
included individuals with as well as without epilepsy20,23,25-27,31. Of these, 20.3% of patients had 146 
epilepsy. In cohorts with more severe ID, a higher rate of patients had epilepsy (Spearman-147 
Rank correlation, p-value = 0.012, rho = 0.89, Supplementary Figure S3), in line with previous 148 
literature4,6. We considered DNV of 1911 healthy siblings of patients with ASD as a control 149 
group. 150 
 151 
DNV in known EE genes in patients with different NDD diagnoses 152 
We first compared DNV in known EE genes between NDDEE, NDDuE, NDDwoE and control 153 
cohorts. We investigated missense and truncating DNV (DNVmis+trunc) in 50 known autosomal 154 
dominant or X-linked EE genes (updated list from19, Supplementary Table 3). We excluded 155 
DNV present in ExAC32 to improve power, as these have been shown to confer no risk to 156 
childhood-onset NDD on a group level33. The frequency of DNVmis+trunc in EE genes was not 157 
significantly different between NDDEE (13.0%±3.1, mean, 95%-CI) and NDDuE (11.5%±1.8, 158 
mean, 95%-CI, p-value = 0.4, Fisher’s Exact Test, Figure 1A, see Supplementary Figure S4 for 159 
individual cohorts), but was significantly greater than in NDDwoE (2.7%±0.5, mean, 95%-CI, 160 
p-value = 4.4x10-46) and in healthy controls (0.3%±0.2, mean, 95%-CI)20. Within three 161 
different NDD diagnoses (ID, ASD [with and without ID], DD), we detected more DNV in 162 
EE genes in individuals with epilepsy than without epilepsy (Cochran–Mantel–Haenszel test, 163 
p-value 3.5x10-43, common OR 4.6, 95%-CI: 3.7 to 5.9, Figure 2B). This suggests a markedly 164 
overlapping genetic spectrum of NDDEE and NDDuE. We subsequently performed DNV 165 
enrichment analyses on the combined cohort of NDDEE+uE.  166 
 167 
Discovery of genes with exome-wide DNV burden in NDD with epilepsy 168 
We compared the numbers of DNV in the combined cohort of NDD with epilepsy (NDDEE+uE), 169 
to the number of DNV expected by a mutational model30 revealing global enrichment of 170 
truncating (2.3-fold, ptrunc= 1 x 10-47, Poisson Exact test, see Online Methods) and missense 171 
(1.6-fold, pmis=2 x 10-33) but not synonymous DNV (0.6 fold, psyn=1.0). We identified 33 genes 172 
with an exome-wide significant burden of DNVmis+trunc (Table 1), of which KCNQ2 (n=21), 173 
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SCN2A (n=20) and SCN1A (n=19) were most frequently mutated. GABRB2 and SNAP25 had 174 
previously no statistical evidence for disease association (see Supplementary Note). Beyond 175 
the 33 genes with exome-wide significant DNV burden, 114 genes had at least two 176 
DNVmis+trunc in our cohort (Supplementary Table 6). After DNV enrichment analysis, we again 177 
excluded DNV in ExAC32 to improve specificity33. 178 
Collectively analysing all patients with NDD with or without epilepsy (n = 6753), we 179 
found 101 genes with exome-wide DNV burden (Supplementary Table 7). Among these 101 180 
genes five were mutated in at least one individual with EE and at least two other individuals 181 
with epilepsy with DNV in the same variant class. Of these, SMARCA2 DYNC1H1 and 182 
SLC35A2 were formerly associated with NDD with epilepsy. KCNQ3 had previously limited 183 
association with NDD with epilepsy and CACNA1E had previously no statistical evidence for 184 
disease association (Genes further described in Supplementary Notes). 185 
 186 
 187 
 188 
Phenotypic, biological and therapeutic properties of genes with DNV burden in NDD with 189 
epilepsy 190 
We aimed to explore whether the 33 genes with DNV burden in NDD with epilepsy 191 
(NDDEE+uE) were associated with specific phenotypes. Analyses of human phenotype 192 
ontology34 (HPO) terms revealed most significant enrichment in genes associated with 193 
“epileptic encephalopathy” (see Online Methods, Supplementary Table 8). After excluding the 194 
529 patients diagnosed with EE from the DNV enrichment analysis, the most significantly 195 
enriched HPO term was still “epileptic encephalopathy” (Bonferroni p-value 3.6 x 10-14), 196 
confirming our previous findings (Figure 1). Per DNV-enriched gene, we plotted distribution 197 
of EE phenotypes, sex and seizure phenotypes of generalized, focal, febrile or spasms 198 
(Supplementary Figure S5 - 6). 199 
Since the disease onset of NDD with epilepsy is typically in infancy and early 200 
childhood, we evaluated expression levels of the 33 genes with DNV burden in the developing 201 
infant brain (expression data: brainspan.org, see Online Methods). At a group level, these 202 
genes showed high levels of brain expression (Supplementary Figure S7A). The DNV-203 
enriched genes were also substantially depleted for truncating and missense variants in the 204 
ExAC control data (Supplementary Figure S7B, S7C). Genes with at least two DNV in 205 
NDDEE+uE, but no significant DNV burden showed similar patterns. 206 
We finally evaluated if genes with DNVmis+trunc in NDD with epilepsy were associated 207 
with therapy. For each gene, we used criteria from the Centre for Evidence-Based Medicine 208 
(CEBM)35 to evaluate the evidence for targeted treatments. Five of the 33 DNV-enriched 209 
genes (SCN1A, SCN2A, SCN8A, KCNQ2, MECP2) had evidence for therapeutic relevance 210 
(CEBM Grade of Recommendation A and B, see Online Methods, Supplementary Table 9). 211 
These five genes accounted for 28% of all DNVmis+trunc in the significantly implicated genes. 212 
Three additional genes (PTEN, CACNA1A, SLC2A1) with at least two DNVmis+trunc, which 213 
were also known disease genes, also had therapeutic relevance according to CEBM criteria. In 214 
total 5% (84/1587) of DNVmis+trunc in NDD with epilepsy were in genes with therapeutic 215 
consequences. According to the guidelines of the American College of Medical Genetics 216 
(ACMG,)36 all DNV that are not in ExAC and that are in known disease genes or genes with 217 
DNV burden in our dataset are categorized as “likely pathogenic”, while we did not apply all 218 
ACMG criteria to individual DNV (see online methods).  219 
 220 
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Comparing DNV between NDD with and without epilepsy 221 
We compared frequencies of DNVmis+trunc in NDD with epilepsy (NDDEE+uE) to NDDwoE across 222 
all 107 DNV-enriched genes (logistic regression, see Online Methods). Increasing age at time 223 
of recruitment increased likelihood of epilepsy (three-year OR 1.11, 95%-CI 1.04 to 1.18, p-224 
value = 3x10-3, individual genes in Supplementary Figure S8). Sex was not associated with 225 
epilepsy status (p-value = 0.5). Individuals with DNVmis were more likely to have epilepsy than 226 
individuals with DNVtrunc (Figure 2, ORmis 2.1, 95%-CI 1.6 to 2.8, p-value 2x10-7). In line with 227 
previous reports15, we observed this pattern on a single gene level for SCN2A (Firth regression, 228 
ORmis 23.5, 95%-CI 3.8 to 277, p-value 0.0003, Table 1). Confirming previous findings24,37, 229 
DNV in ion channel genes were associated with epilepsy (OR 6.0, 95%-CI 3.9 to 9.2, p-value 230 
1x10-16). 83% (110/133) of DNV in ion channel genes were DNVmis. However, in the subset of 231 
910 DNV not in ion channel genes, DNVmis were still associated with epilepsy (OR 1.5, p-value 232 
0.005, 95%-CI 1.1 to 2.1), implying that the effect of DNVmis on epilepsy was not entirely 233 
driven by ion channel genes. We observed a higher rate of DNVmis in NDDEE than in NDDuE, 234 
though only with nominal significance (Fisher’s exact test, OR 1.8, 95%-CI 1.04 to 3.4, p-value 235 
0.03, Supplementary Figure S9B). Four genes were more frequently mutated in NDD with 236 
epilepsy (NDDEE+uE) than NDDwoE (Fisher’s Exact Test, Figure 2A/2B, Table 1, Supplementary 237 
Table 10). With the exception of SCN1A, frequencies of DNV were not significantly different 238 
per gene between NDDEE and NDDuE for DNVmis or DNVtrunc (Supplementary Figure S9, 239 
Supplementary Table 11).  240 
 241 
Evaluation of diagnostic gene panels for epilepsy disorders 242 
Targeted sequencing of disease-specific gene panels is widely employed in diagnostics of 243 
epilepsies18,19. We compared our results to 24 diagnostic panels for epilepsy or EE (see Online 244 
Methods, full list in Supplementary Table 12). In total, the 24 different panels covered 358 245 
unique genes (81.5 ± 8.8 genes per panel, mean ± sd). Applying these 24 diagnostic panels on 246 
our data set would only have detected on average 59% of DNVmis+trunc in the 33 DNV-enriched 247 
genes (Supplementary Figure S10). However, similar to most other research studies involving 248 
clinical WES7, we cannot fully assess the extent of potential pre-screening. We investigated 249 
whether genes in the 24 panels had some evidence for disease association given the following 250 
features that we (and others23,33) observed in genes with DNV burden in NDD: depletion for 251 
truncating and missense variants in ExAC32 controls as well as brain expression (Online 252 
Methods, Supplementary Figure S8). We restricted this analysis to autosomal dominant and 253 
X-linked acting panel genes (ndominant+X-linked = 191, Supplementary Table 13). 95% (52/55) of 254 
panel genes that had two or more DNVmis+trunc in our study were both constraint and brain-255 
expressed. However, only 63% (86/136) of panel genes with one or less DNVmis+trunc in our 256 
study were constraint and brain-expressed (Fisher’s exact test, OR 10.2, 95%-CI 3.0 to 53.0, p-257 
value 2.3 x 10-6). We applied evidence of disease association as defined by the ClinGen Gene 258 
Curation Workgroup38, to those 50 panel genes lacking two of the criteria DNV/brain 259 
expression/constraint. We found that ten of the 50 genes had no, eight had limited and seven 260 
had conflicting published evidence for disease association (Supplementary Table 14). Thirteen 261 
genes showed moderate, strong or definitive evidence for association to entities where neither 262 
NDD nor epilepsy were major features which may partly be explained by a panel design 263 
containing genes associated with diseases beyond the spectrum of NDD (for further details 264 
see Online Methods and Supplementary Figure S10).  265 
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Discussion 266 
 267 
In this study, we systematically investigated DNV in NDD with and without epilepsy. In NDD 268 
with epilepsy, we could hardly distinguish individuals ascertained for epileptic 269 
encephalopathy and NDD with unspecified epilepsy on a genetic level. Thus, we conclude that 270 
these phenotype groups share a spectrum of disease genes predominantly including genes 271 
initially reported as EE genes. We identified 33 genes with DNV burden in NDD with epilepsy, 272 
of which the majority was expressed in the infant brain and depleted for functional variation 273 
in ExAC32, as previously described for NDD genes23,33. We report statistically robust disease 274 
association for SNAP25, GABRB2 and CACNA1E, which was previously lacking 275 
(Supplementary Notes).  276 
 277 
We found, that individuals with DNVmis were generally more likely to have epilepsy than 278 
individuals with DNVtrunc. This association was largely driven by ion channel genes, which 279 
confirms longstanding statements that many epilepsy disorders act as channelopathies2,37,24. 280 
Heterozygous DNVmis have been shown to cause epilepsy via dominant negative (e.g. 281 
KCNQ239) or gain-of-function (e.g. SCN8A40) effects on ion channels. On the individual gene 282 
level, missense variants in SCN2A15 and SCN8A41 were more strongly implicated in epilepsy 283 
than protein truncating variants, which we statistically confirm for SCN2A. Yet, we found that 284 
DNVmis were also associated with epilepsy independent of ion channel genes. This may imply 285 
that alteration of protein function quantitatively plays a larger role than haploinsufficiency42 286 
in the pathophysiology of NDD with epilepsy compared to NDD without epilepsy. We found 287 
multiple gene sets enriched for DNVmis in epilepsy compared to no epilepsy (see 288 
Supplementary Note). The majority was related to ion channels, while others related to 289 
neuronal cells (e.g. axon part, synaptic transmission). However, biological interpretation 290 
should be done with caution given that previous studies have found that many of these gene 291 
sets share a large number of underlying genes22 and gene annotations are biased43. We further 292 
replicate a previous finding that the rate of epilepsy was correlated with severity of intellectual 293 
disability4-6, implying that brain function could contribute to epileptogenesis or genetic 294 
variants cause both epilepsy and NDD. Alternatively, severe epileptic activity may also 295 
damage brain function and thereby contribute to NDD, which constitutes the original 296 
definition of EE9,17. This is supported by many cases of clinical regression after onset of 297 
epilepsy and improvement of NDD through seizure control. 298 
 299 
In NDD with epilepsy we found no genetic differences between unspecified epilepsy and EE, 300 
with the exception of SCN1A (Supplementary Note). Phenotypic heterogeneity has been 301 
described for the majority of EE genes1,11, i.e. variants in the same gene could lead to a 302 
spectrum of different phenotypes. Due to pleiotropy, individuals that carry a pathogenic DNV 303 
in an EE gene and fulfil diagnostic criteria of EE may also be eligible for another NDD 304 
diagnosis and thus by chance be assigned to an ASD, DD or ID and not an EE screening 305 
cohort. In line with this hypothesis, we found typically EE-associated seizure types (e.g. 306 
epileptic spasms) in cohorts with unspecified epilepsy. Some of the diagnostic criteria for 307 
EE1,10 may present ambiguously, leading to uncertainty in terminology17. Thus, 43% (21/49) of 308 
individuals diagnosed with EE in the Epi4K-E224 study initially presented with DD prior to 309 
seizure onset conflicting with the original definition of EE3,17. Clear phenotypic distinction 310 
between encephalopathic versus non-encephalopathic epilepsies may therefore be difficult. 311 
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Accordingly, mechanisms that result in an encephalopathic course of a genetic NDD remain 312 
elusive.  313 
 314 
Restricting DNA sequencing or DNA sequence analysis to panels of known disease genes is 315 
widely used in diagnosis of genetic diseases including epilepsy (19, 100,000 genomes project 316 
[www.genomicsengland.co.uk]). We confirmed that epilepsy gene panels from diagnostic 317 
laboratories differ substantially in gene content18 with at least 25 genes with low evidence for 318 
disease association (ClinGen criteria38). Statistically not robust gene-disease associations 319 
occasionally resulted in false-positive reports of causality posing challenges for correct 320 
diagnosis in research and clinical settings11,44. Our data provide grounds for replacing genes 321 
with limited evidence by genes with higher evidence in the design of gene panels for NDD 322 
with epilepsy. 323 
 324 
Therapeutic approaches, tailored to the patient’s underlying genetic variant, have successfully 325 
been applied for several EE2 including treatment with ezogabine in KCNQ2 encephalopathy45 326 
or ketogenic diet in SLC2A1-related disorders46. 5% of DNVmis+trunc in our study were in eight 327 
genes (Supplementary Table 9) for which we could confirm therapeutic consequences with 328 
established evidence-based medicine criteria35. This finding reinforces the urgency of making 329 
a genetic diagnosis in NDD with epilepsy. We expect that with increasing understanding of 330 
the underlying pathomechanisms, the group of genetic epilepsies with relevant therapeutic 331 
consequences will continue to grow.  332 
 333 
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Figure legends 375 
 376 
Figure 1.  DNVmis+trunc in EE genes in different cohorts of NDD. A, The frequency of 377 
DNVmis+trunc in EE genes is not significantly different between patients with NDDEE (red) and 378 
NDDuE (blue), but higher than NDDwoE (yellow) or healthy controls (grey). B, Proportion of 379 
DNV in EE genes in patients with versus without epilepsy across different NDD (DD, ASD, 380 
ID). P-values are plotted next to respective odds ratios (two-sided Fisher’s exact test for 381 
individual cohorts, Cochran-Mantel-Haenszel test for combined cohorts). Bars represent the 382 
95%-CI of the point estimates. Low-coverage exons and cohorts were excluded from the 383 
analysis. 384 
 385 
 386 
Figure 2. DNV in NDD with epilepsy (NDDEE+uE, n= 1874) versus without epilepsy 387 
(NDDwoE, n= 4728) in 107 genes with significant DNV burden. A, 524 DNVmis B, 561 388 
DNVtrunc. Genes with different DNV frequencies in individuals with versus without epilepsy 389 
are labeled (two-sided Fisher’s Exact test; blue: nominal significance, p-value < 0.05; red: 390 
significant after correcting for 266 tests). The dotted line represents equal frequency of DNV 391 
in NDD with and without epilepsy. Low-coverage exons and cohorts were excluded from the 392 
analysis.  393 
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Tables 394 
 395 
Table 1. Genes with exome-wide DNV burden in NDD with epilepsy. 396 
 397 
 398 
Gene  
Epilepsy 
DNVtrunc DNVmis DNVmis+trunc  
yes no yes no yes+no 
KCNQ2 0 1 21 3 25
SCN2A 2 12 18 5 37
SCN1A 8 0 11 0 19
CHD2 9 1 3 2 15
SYNGAP1 10 7 1 2 20
STXBP1 4 3 7 5 19
SCN8A 0 1 10 3 14
MEF2C 4 1 5 0 10
SLC6A1 2 1 7 3 13
DNM1 0 0 9 2 11
EEF1A2 0 0 8 3 11
CDKL5 2 0 6 0 8
DYRK1A 7 9 0 5 21
SMC1A 7 0 0 2 9
GABRB3 0 0 7 1 8
KIAA2022 6 0 0 0 6
ASXL3 6 12 0 0 18
WDR45 5 5 1 0 11
ARID1B 6 28 0 2 36
GNAO1 0 1 6 2 9
ALG13 0 0 6 0 6
KCNH1 0 0 6 2 8
GRIN2B 0 3 6 9 18
HNRNPU 5 2 0 1 8
PURA 3 4 2 4 13
GABRB2 0 0 5 1 6
COL4A3BP 0 0 5 4 9
MECP2 2 5 3 5 15
FOXG1 2 3 3 3 11
ANKRD11 4 28 0 2 34
SNAP25 1 0 3 0 4
DDX3X 3 19 1 11 34
IQSEC2 3 2 1 3 9
 *Genes in order of decreasing numbers of DNVmis+trunc in NDD with epilepsy   399 
 13 
 
References 400 
 401 
1. McTague, A., Howell, K.B., Cross, J.H., Kurian, M.A. & Scheffer, I.E. The 402 
genetic landscape of the epileptic encephalopathies of infancy and 403 
childhood. Lancet Neurol 15, 304-16 (2016). 404 
2. Myers, C.T. & Mefford, H.C. Advancing epilepsy genetics in the genomic 405 
era. Genome Med 7, 91 (2015). 406 
3. Scheffer, I.E. et al. ILAE classification of the epilepsies: Position paper of 407 
the ILAE Commission for Classification and Terminology. Epilepsia (2017). 408 
4. McGrother, C.W. et al. Epilepsy in adults with intellectual disabilities: 409 
prevalence, associations and service implications. Seizure 15, 376-86 410 
(2006). 411 
5. Thomas, S., Hovinga, M.E., Rai, D. & Lee, B.K. Brief Report: Prevalence of 412 
Co-occurring Epilepsy and Autism Spectrum Disorder: The U.S. National 413 
Survey of Children's Health 2011-2012. J Autism Dev Disord 47, 224-229 414 
(2017). 415 
6. Robinson, E.B. et al. Autism spectrum disorder severity reflects the 416 
average contribution of de novo and familial influences. Proc Natl Acad Sci 417 
U S A 111, 15161-5 (2014). 418 
7. Deciphering Developmental Disorders, S. Prevalence and architecture of 419 
de novo mutations in developmental disorders. Nature 542, 433-438 420 
(2017). 421 
8. Li, J. et al. Genes with de novo mutations are shared by four 422 
neuropsychiatric disorders discovered from NPdenovo database. Mol 423 
Psychiatry 21, 290-7 (2016). 424 
9. Berg, A.T. et al. Revised terminology and concepts for organization of 425 
seizures and epilepsies: report of the ILAE Commission on Classification 426 
and Terminology, 2005-2009. Epilepsia 51, 676-85 (2010). 427 
10. Berg, A.T. & Millichap, J.J. The 2010 revised classification of seizures and 428 
epilepsy. Continuum (Minneap Minn) 19, 571-97 (2013). 429 
11. Helbig, I. & Tayoun, A.A. Understanding Genotypes and Phenotypes in 430 
Epileptic Encephalopathies. Mol Syndromol 7, 172-181 (2016). 431 
12. Trump, N. et al. Improving diagnosis and broadening the phenotypes in 432 
early-onset seizure and severe developmental delay disorders through 433 
gene panel analysis. J Med Genet 53, 310-7 (2016). 434 
13. Depienne, C. et al. Spectrum of SCN1A gene mutations associated with 435 
Dravet syndrome: analysis of 333 patients. J Med Genet 46, 183-91 (2009). 436 
14. Weckhuysen, S. et al. Extending the KCNQ2 encephalopathy spectrum: 437 
clinical and neuroimaging findings in 17 patients. Neurology 81, 1697-703 438 
(2013). 439 
15. Wolff, M. et al. Genetic and phenotypic heterogeneity suggest therapeutic 440 
implications in SCN2A-related disorders. Brain (2017). 441 
16. Stamberger, H. et al. STXBP1 encephalopathy: A neurodevelopmental 442 
disorder including epilepsy. Neurology 86, 954-62 (2016). 443 
17. Howell, K.B., Harvey, A.S. & Archer, J.S. Epileptic encephalopathy: Use and 444 
misuse of a clinically and conceptually important concept. Epilepsia 57, 445 
343-7 (2016). 446 
 14 
 
18. Chambers, C., Jansen, L.A. & Dhamija, R. Review of Commercially Available 447 
Epilepsy Genetic Panels. J Genet Couns 25, 213-7 (2016). 448 
19. Lemke, J.R. et al. Targeted next generation sequencing as a diagnostic tool 449 
in epileptic disorders. Epilepsia 53, 1387-98 (2012). 450 
20. Iossifov, I. et al. The contribution of de novo coding mutations to autism 451 
spectrum disorder. Nature 515, 216-21 (2014). 452 
21. Zaidi, S. et al. De novo mutations in histone-modifying genes in congenital 453 
heart disease. Nature 498, 220-3 (2013). 454 
22. Singh, T. et al. The contribution of rare variants to risk of schizophrenia in 455 
individuals with and without intellectual disability. Nat Genet (2017). 456 
23. Lelieveld, S.H. et al. Meta-analysis of 2,104 trios provides support for 10 457 
new genes for intellectual disability. Nat Neurosci 19, 1194-6 (2016). 458 
24. EuroEpinomics & Epi4K. De novo mutations in synaptic transmission 459 
genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 460 
95, 360-70 (2014). 461 
25. Hamdan, F.F. et al. De novo mutations in moderate or severe intellectual 462 
disability. PLoS Genet 10, e1004772 (2014). 463 
26. de Ligt, J. et al. Diagnostic exome sequencing in persons with severe 464 
intellectual disability. N Engl J Med 367, 1921-9 (2012). 465 
27. Rauch, A. et al. Range of genetic mutations associated with severe non-466 
syndromic sporadic intellectual disability: an exome sequencing study. 467 
Lancet 380, 1674-82 (2012). 468 
28. Helbig, K.L. et al. Diagnostic exome sequencing provides a molecular 469 
diagnosis for a significant proportion of patients with epilepsy. Genet Med 470 
18, 898-905 (2016). 471 
29. Fischbach, G.D. & Lord, C. The Simons Simplex Collection: a resource for 472 
identification of autism genetic risk factors. Neuron 68, 192-5 (2010). 473 
30. Samocha, K.E. et al. A framework for the interpretation of de novo 474 
mutation in human disease. Nat Genet 46, 944-50 (2014). 475 
31. McRae, J.F. et al. Prevalence, phenotype and architecture of 476 
developmental disorders caused by de novo mutation. bioRxiv (2016). 477 
32. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 478 
humans. Nature 536, 285-91 (2016). 479 
33. Kosmicki, J.A. et al. Refining the role of de novo protein-truncating 480 
variants in neurodevelopmental disorders by using population reference 481 
samples. Nat Genet (2017). 482 
34. Reimand, J. et al. g:Profiler-a web server for functional interpretation of 483 
gene lists (2016 update). Nucleic Acids Res 44, W83-9 (2016). 484 
35. OCEBM Levels of Evidence Working Group* (Jeremy Howick, I.C.J.L.L., 485 
Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan 486 
Moschetti, Bob Phillips, Hazel Thornton, Olive Goddard and Mary 487 
Hodgkinson). The Oxford Levels of Evidence. in Oxford Centre for 488 
Evidence-Based Medicine. (2009). 489 
36. Richards, S. et al. Standards and guidelines for the interpretation of 490 
sequence variants: a joint consensus recommendation of the American 491 
College of Medical Genetics and Genomics and the Association for 492 
Molecular Pathology. Genet Med 17, 405-24 (2015). 493 
37. Mulley, J.C., Scheffer, I.E., Petrou, S. & Berkovic, S.F. Channelopathies as a 494 
genetic cause of epilepsy. Curr Opin Neurol 16, 171-6 (2003). 495 
 15 
 
38. Rehm, H.L. et al. ClinGen--the Clinical Genome Resource, 496 
www.clinicalgenome.org/site/assets/files/2657/current_clinical_validity497 
_classifications.pdf. N Engl J Med 372, 2235-42 (2015). 498 
39. Weckhuysen, S. et al. KCNQ2 encephalopathy: emerging phenotype of a 499 
neonatal epileptic encephalopathy. Ann Neurol 71, 15-25 (2012). 500 
40. Wagnon, J.L. et al. Pathogenic mechanism of recurrent mutations of 501 
SCN8A in epileptic encephalopathy. Ann Clin Transl Neurol 3, 114-23 502 
(2016). 503 
41. Blanchard, M.G. et al. De novo gain-of-function and loss-of-function 504 
mutations of SCN8A in patients with intellectual disabilities and epilepsy. 505 
J Med Genet 52, 330-7 (2015). 506 
42. Wilkie, A.O. The molecular basis of genetic dominance. J Med Genet 31, 89-507 
98 (1994). 508 
43. Haynes, W., Tomczak, A. & Khatri, P. Gene annotation bias impedes 509 
biomedical research. bioRxiv (2017). 510 
44. MacArthur, D.G. et al. Guidelines for investigating causality of sequence 511 
variants in human disease. Nature 508, 469-76 (2014). 512 
45. Millichap, J.J. et al. KCNQ2 encephalopathy: Features, mutational hot spots, 513 
and ezogabine treatment of 11 patients. Neurol Genet 2, e96 (2016). 514 
46. De Giorgis, V. & Veggiotti, P. GLUT1 deficiency syndrome 2013: current 515 
state of the art. Seizure 22, 803-11 (2013). 516 
 517 
  518 
 16 
 
Online Methods   519 
 520 
Patient cohorts 521 
For this study, we ascertained 8,529 patients with the following neurodevelopmental disorders 522 
(NDD): developmental delay (DD31, n=4293), autism spectrum disorder (ASD20, n=2508), 523 
epileptic encephalopathy24,28 (NDDEE, n=529), intellectual disability23,25-27 (ID, n=1035), and 524 
epilepsy with NDD28 (n=164). From this cohort, we selected 6753 individuals, for which the 525 
presence or absence of epilepsy was ascertained and of whom ca. 88% had ID (based on 526 
assumption of 81.7% ID in the DDD study7, 89.8% ID in a diagnostic cohort from 527 
AmbryGenetics28 and 100% ID in all other cohorts.) Among individuals with ASD who were 528 
phenotyped within the Simon Simplex Consortium29, we restricted our analysis to patients 529 
with ID (IQ < 70) as it has been shown that DNV play only a minor role, in normal IQ ASD6,30. 530 
Previously sequenced trios (n = 1911), from unaffected siblings of a child with ASD20,29, served 531 
as control trios. For our main analyses, we stratified this combined cohort of patients with 532 
NDD for patients comorbid or primarily diagnosed with epilepsy (NDDEE+uE, n=1942)20,29. 533 
Two EE cohorts and one ID cohort comprising a combined 144 patients were not previously 534 
published; one cohort was only partly published (see Supplementary Table 1). Medical 535 
doctors, mostly clinical geneticists, but also neurologists, paediatricians and for ASD29 some 536 
primary care physicians reported out phenotypes, including presence of epilepsy, in all 537 
patients. Our analysis is based on the assumption that medical professionals are sufficiently 538 
qualified to diagnose the presence or absence of epilepsy correctly. 539 
 540 
Subphenotypes 541 
We obtained information on specific EE syndromes on 98% of 518/529 individuals with 542 
NDDEE (see main text). We obtained specific seizure types (febrile, focal, spasms, generalized) 543 
for 55% (140/256) and age of seizure onset for 30% (77/256) of individuals with DNVmis+trunc in 544 
genes with DNV burden in NDDEE+uE. (See Supplementary Figure S5 and S6). We did not 545 
obtain EEG data per patient. Some patients may have developed epilepsy after inclusion in the 546 
study, so we ascertained age at recruitment, that we obtained for 94% (1087/1157) of all 547 
individuals with NDD with DNVmis+trunc in DNV-enriched genes (median age at recruitment: 548 
74.8 months). We obtained age of seizure onset for 30% (77/256) of individuals with epilepsy 549 
and DNVmis+trunc in DNV-enriched genes (Supplementary Figure S5). We identified 30 550 
individuals with potentially epilepsy-relevant brain malformations (abnormalities of neuronal 551 
migration, structural abnormalities of corpus callosum, midbrain, brainstem as schiz-, megal-, 552 
holoprosencephaly) in individuals with DNVmis+trunc in DNV-enriched genes (29 from DDD29, 553 
1 from Hamdan et al.7). 11 of them (37%) also had seizures.  554 
 555 
Whole exome sequencing of parent-patient trios 556 
In all cohorts, both patients and their unaffected parents underwent whole exome sequencing 557 
(WES). Variants that were not present in either parent were considered de novo variants 558 
(DNV). 1942 individuals with NDD with epilepsy (NDDEE+uE) had 1687 DNVmis and 396 559 
DNVtrunc (i.e. stopgain, frameshift, essential splice site). 4811 individuals with NDDwoE had 560 
4227 DNVmis and 1120 DNVtrunc (Supplementary Table 2, for individual cohorts see 561 
Supplementary Figure S3). The study was approved by the ethics committee of the University 562 
of Leipzig (224/16-ek, 402/16-ek). The DDD cohort of this study has UK Research Ethics 563 
Committee approval (10/H0305/83, granted by the Cambridge South Research Ethics 564 
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Committee and GEN/284/12, granted by the Republic of Ireland Research Ethics Committee). 565 
A list of all published and unpublished cohorts used in this paper can be found in 566 
Supplementary Table 1. 567 
 568 
Sequencing pipelines of previously unpublished/partly published cohorts (cohorts 8 -11) 569 
Libraries were prepared from parents’ and patients’ DNA, exome captured and sequenced on 570 
Illumina sequencers. Raw data was processed and technically filtered with established 571 
pipelines at the respective academic or diagnostic laboratories. For Cohort 8 (Ambry 572 
Genetics), diagnostic WES was performed on parent-offspring trios at Ambry Genetics (Aliso 573 
Viejo, CA) in 216 individuals with a history of seizures described in 28. Genomic DNA 574 
extraction, exome library preparation, sequencing, bioinformatics pipeline, and data analyses 575 
were performed as previously described47. The following variants filters were applied to 576 
generate a list of high confident de novo variant calls: 1) mutation base coverage >= 20x in all 577 
members of the trio; 2) heterozygous read ratio in probands >30% and <80%; 3) heterozygous 578 
read ratio in parents <2%; 4) genotype quality cutoffs SNV > 100 and indels > 300 and 5) 579 
exclusion of known sequencing artefacts (based on Ambry Genetics’ internal databases). For 580 
cohorts 9 (EuroEPINOMICS RES) and 10 (DFG atypical EE), genomic DNA extraction, 581 
exome library preparation, sequencing, bioinformatics pipeline, and data processing were 582 
performed as previously described48. The following filtering criteria were applied: read depth 583 
> 30, frequency of alternative allele between 30-70% for the child and not present in the 584 
parents, a minimum VQSLOD genotype quality score of -8, Caucasian population allele 585 
frequency < 1%, variations on targeted regions + flanking 100bp. In order to exclude pipeline 586 
specific artifacts, we also filtered against an in-house cohort of variations, which were created 587 
with the same analysis pipeline. For cohort 11 (University of Leipzig) genomic DNA 588 
extraction, exome library preparation, sequencing, bioinformatics pipeline, and data analyses 589 
were performed as previously described49. Quality filtering of sequencing reads in both 590 
parents and children was done according to the following criteria: read depth > 20, genotype 591 
quality > 500, frequency of alternative allele between 30 and 70% for the child and not present 592 
in the parents, frequency < 1% in internal database, variant called by at least two different 593 
genotype callers. 594 
 595 
False positive rates of DNV 596 
In cohorts 1 to 4, all DNV were validated by Sanger sequencing to eliminate false positive calls. 597 
In cohorts 5 to 7, through random selection of variants for Sanger validation, the false positive 598 
rate was estimated to be approximately 1.4% and < 5 %, respectively. In the clinical cohorts 8 599 
to 11, variants defined as variants worth reporting back to patients (variants of unknown 600 
significance or [likely] pathogenic) are normally validated by Sanger sequencing. With this 601 
experience, false discovery rates in these cohorts were estimated to be < 5% (personal 602 
communications).  603 
 604 
Annotation and Filtering 605 
DNV files were generated and quality-filtered by the individual groups. All DNV were re-606 
annotated with the following pipeline. Variants were annotated with Ensembl’s Variant Effect 607 
Predictor (http://grch37.ensembl.org/Homo_sapiens/Tools/VEP) of version 82 using 608 
database 83 of GRCh37 as reference genome. Per variant, the transcript with the most severe 609 
impact, as predicted by VEP, was selected for further analyses. The decreasing order of variant 610 
impacts was HIGH, MODERATE, MODIFIER, LOW. Only protein – altering DNV (DNVmis 611 
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or DNVtrunc [premature stop codon, essential splice site, frameshift]) were included in further 612 
analyses. Synonymous DNV (DNVsyn) were analysed as a negative control, as most DNVsyn 613 
have no effect on amino acid sequence in the protein. Variants that were present in ExAC32, 614 
an aggregation of 60,706 exome sequences from adult individuals without severe childhood-615 
onset diseases, were excluded after DNV enrichment, as these have been shown to convey no 616 
detectable risk to NDD on a group level33. For DNV rates per cohort see Supplementary 617 
Figure S2. We did not investigate pathogenicity of individual DNV according to the guidelines 618 
of the American College of Medical Genetics (ACMG). However, ACMG criteria PS2 (de 619 
novo occurrence, with maternity and paternity confirmed) and PM2 (absence from controls) 620 
apply to all DNV in our cohort. The combination of PS2 and PM2 classifies a variant as at 621 
least “likely pathogenic”. ACMG criteria are only applicable to variants in disease associated 622 
genes36. Therefore, all DNV in known disease genes and genes with genome-wide DNV 623 
burden in our dataset are presumed likely pathogenic DNV. 624 
 625 
Harmonization of different cohorts 626 
The core analysis of our study is the enrichment of DNVmis+trunc compared to expectation by a 627 
mutational model in individuals with NDDEE+uE. For this analysis, we were conservative in 628 
assuming that every gene was well captured across all cohorts. However, when comparing 629 
DNV burden across different phenotypes we aimed to separate technical from biological 630 
differences with the following methods. In exome sequencing, different capture solutions 631 
capture specific exonic regions with different efficiencies. These differences have shown to be 632 
quite stable within and across different samples of the same capture kits50. We therefore 633 
generated a list of exons that displayed consistent high coverage across different capture 634 
solutions. We collected published and internal data aiming for the highest possible variety of 635 
capture kits using 3,000 samples of 5 different capture kits, including NimbleGen SeqCap v2 636 
and v3, Agilent SureSelect v2, v3, and v5). We generated a list of exons where at least 80% of 637 
all samples had at least 10x coverage. We excluded the oldest capture kits before calculating 638 
the high coverage exons as well as excluding the two oldest cohorts 26,27 from our list of DNV. 639 
Restricting to high coverage regions resulted in a loss of ca. 11% of DNV in DNV-enriched 640 
genes. We consequently performed all genotype phenotype comparisons across cohorts 641 
(Figures 1A, 2, Supplementary Figures S6-10) with this restricted DNV set. Further, we 642 
compared the frequency of DNVsyn across all cohorts and excluded cohorts of which DNVsyn 643 
were not available. In the subset of DNV in high coverage exons, rates of supposedly neutral 644 
DNVsyn were not different between individuals with and without epilepsy (Poisson Exact test, 645 
p-value = 0.48, RR=0.99), NDDuE and NDDEE (p-value = 0.65, RR= 0.94) or NDD and 646 
controls (p-value = 0.58, RR=0.99). The frequency of DNVmis+trunc was also not different 647 
between individuals with and without epilepsy (p-value=0.5, RR=1.02). Our chances to 648 
identify DNVmis+trunc in EE genes in the epilepsy cohort were therefore not inflated by a higher 649 
baseline rate of DNVmis+trunc in comparison to NDDwoE. We reannotated all DNV in the same 650 
way as described above. 651 
 652 
Statistical analysis  653 
All statistical analyses were done with the R programming language (www.r-project.org). 654 
Fisher's Exact Test for Count Data, Wilcoxon rank sum test, Poisson Exact Test, Cochran-655 
Mantel-Haenszel test, logistic regression, Firth regression, Spearman correlation, Welch two-656 
sided t-test and calculation of empirical p-values were performed as referenced in the results. 657 
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For datasets assumed to be normally distributed after visual inspection, mean and standard 658 
deviation (sd) are written as mean ± sd. When performing Poisson Exact Tests, we reported 659 
effect size as rate ratio (RR), which is the quotient of the two rates compared in the test. For 660 
Fisher’s Exact Test and logistic regression analyses, we reported odds ratios (OR). 95% 661 
confidence intervals were abbreviated as 95%-CI.  662 
 663 
Code availability 664 
The R code used to perform the statistical analyses and figures is available upon request. 665 
 666 
DNV enrichment analyses 667 
To identify genes with a significant DNV burden, we compared numbers of observed with 668 
numbers of expected missense, truncating and synonymous DNV per gene using an 669 
established framework of gene-specific mutation rates30. The analysis was done with the R 670 
package denovolyzer51, that compares observed versus expected DNV using a Poisson Exact 671 
test. We corrected the obtained p-values with the Bonferroni method for the number of genes 672 
for which gene specific mutation rates30 were available (n= 18225) and six tests resulting in a 673 
p-value significance threshold of 5x10-7. Genes that passed that significance threshold for 674 
either missense, truncating or both missense plus truncating DNV were considered genes 675 
with an exome-wide DNV burden. To compare DNV between disease groups, DNV 676 
enrichment analyses were carried out in the cohort of all patients with NDD (n=6753) as well 677 
as in patients with epilepsy (NDDEE+uE, n=1942) and without epilepsy (NDDwoE, n=4811), but 678 
only genes with a DNVmis+trunc burden in the NDD with epilepsy cohort and the combined 679 
NDD cohort were reported. 680 
 681 
HPO enrichment analyses  682 
Significantly enriched Human phenotype ontology (HPO) terms were computed with the R 683 
package of g:Profiler34, using ordered enrichment analysis on significance-ranked proteins 684 
(see Supplementary Table 8). Different gene sets were queried using the background gene set 685 
of all 18225 genes for which gene specific mutation rates were available30. Only terms that 686 
were statistically significant with a Bonferroni corrected p-value < 0.01 were reported, as our 687 
negative controls (genes with at least two DNVmis+trunc in healthy control) were not enriched 688 
for any functional categories below this p-value. 689 
 690 
Therapeutic relevance 691 
To assess if DNV in our cohort were in genes of therapeutic relevance, we searched the 692 
literature for treatment recommendations for all established disease genes with at least two 693 
DNVmis+trunc in our NDD with epilepsy cohort. We rated the publications with the 694 
standardized score of the Oxford Centre for Evidence-Based Medicine35. We only reported 695 
and considered genes for which at least one treatment recommendation achieved level of 696 
evidence of II or higher. For a list of all genes and levels of evidence see Supplementary Table 697 
9. 698 
 699 
Acquisition and processing of brain gene expression data 700 
We downloaded the Developmental Transcriptome dataset of ‘BrainSpan: Atlas of the 701 
Developing Human Brain’ (www.brainspan.org, funded by ARRA Awards 1RC2MH089921-702 
01, 1RC2MH090047-01, and 1RC2MH089929-01, 2011). The atlas includes RNA sequencing 703 
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data generated from tissue samples of developing postmortem brains of neurologically 704 
unremarkable donors covering 8 to 16 brain structures. We extracted brain expression data 705 
from the 5 donors that were infants aged 0 to 12 months. Per gene, we obtained the median 706 
RPKM value of all infant individuals and across brain regions. In all calculations and figures 707 
gene expression values are displayed as median (log2 + 1)-transformed RPKM values. We 708 
defined infant brain gene expression as median (log2 + 1)-transformed RPKM value > 1. 709 
More details about tissue acquisition and sequencing methodology can be found in the 710 
BrainSpan website’s documentation. 711 
 712 
Evaluation of genes’ intolerance to protein altering variants  713 
We assessed individual gene tolerance to truncating or missense variants in the general 714 
population with the pLI score (probability of being loss-of-function intolerant) and missense 715 
z-score. These scores indicate depletion of truncating and missense variants in ExAC32 (60,706 716 
individuals without childhood onset diseases), respectively. We used gene constraint cut-offs 717 
>0.9 for pLI and >3.09 for missense-z scores as recommended by the score developers32. We 718 
calculated empirical p-values to evaluate if pLI scores of exome-wide and nominally DNV-719 
enriched genes were significantly higher compared to pLI scores of random gene sets as 720 
described in23. Briefly, we computed the expected pLI for a given gene set with size n by 721 
randomly drawing 1,000,000 gene sets with size n from the total 18,225 pLI annotated genes. 722 
We computed, how many times the median pLI score of randomly sampled gene sets would 723 
exceed the median pLI of the gene set under investigation. To that number we added 1 and 724 
divided by the number of total samplings +1 to obtain the empirical p-value. 725 
 726 
Comparing DNV in NDDEE, NDDuE and NDDwoE 727 
We investigated DNVmis+trunc in NDDEE+uE+woE across all 107 genes that were DNV-enriched in 728 
NDDEE+uE, NDDwoE and/or NDDEE+uE+woE. We restricted our analysis to DNV not in ExAC23 and 729 
in high coverage regions. To investigate, if age at time of recruitment, sex or variant class 730 
(DNVmis/DNVtrunc) influenced the presence of epilepsy, we tested them as covariates in a 731 
logistic regression model with epilepsy as response variable. We aimed to explore, whether 732 
DNV in NDD with epilepsy might be associated with ion channels compared to NDD without 733 
epilepsy, as it is a long-established hypothesis, that many epilepsies are channelopathies37. We 734 
extracted a comprehensive gene set of 237 known ion channel genes from 1766 previously 735 
described22 curated gene sets derived from public pathway databases and publications (see 736 
Supplementary Note). To investigate if ion channel genes were associated with epilepsy we 737 
included annotation as ion channel gene as a categorical predictor in the logistic regression 738 
model. We used Firth regression to assess the effect of variant class on the presence of epilepsy 739 
for individual genes. We used Fisher’s Exact test to compare frequencies of DNV per gene 740 
between phenotype groups. To account for multiple testing, we corrected p-values for the 741 
number of tests performed (Bonferroni method). 742 
 743 
Diagnostic gene panels for epileptic encephalopathy/ comprehensive epilepsy from 24 academic/ 744 
commercial providers 745 
We set out to compare our results to diagnostic gene panels for epileptic encephalopathy of 746 
international commercial and academic providers. We searched the Genetic Testing Registry 747 
(GTR)52 of NCBI (date: 01/2017) for providers of tests for “Epileptic encephalopathy, 748 
childhood-onset” and identified 16 diagnostic epilepsy panels. We excluded 3 panels with < 749 
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20 or > 200 genes and added 11 additional diagnostic providers not registered at GTR to 750 
evaluate 24 diagnostic panels targeting epilepsy in general (n=11) or EE specifically (n=13). 751 
The gene content covered in each of the 24 gene panels can be found in Supplementary Table 752 
11. Gene lists were freely available for download at the respective providers’ websites. For each 753 
of the 33 genes with DNV burden in NDD with epilepsy, we calculated to what proportion 754 
they were included in 24 commercial or academic providers of gene panels for epileptic 755 
encephalopathy/comprehensive epilepsy. For each gene, we then multiplied the percentage of 756 
inclusion in any of the 24 panels by the total number of DNVmis+trunc of that gene in the cohort 757 
of 1942 individuals with NDDEE+uE.  758 
We investigated if there were genes in the 24 diagnostic gene panels without evidence for 759 
implication in NDD with epilepsy. We focused on 191 dominant or X-linked panel genes 760 
(listed in Supplementary Table 14). We tested these genes for three criteria of association with 761 
NDD with epilepsy: Firstly, if genes had at least two DNVmis+trunc in our study; secondly, 762 
whether genes were expressed in the infant brain defined by a median RPKM of all samples 763 
and brain regions > 1; thirdly, whether genes had a pLI > 0.9 or missense z-score > 3.09 764 
indicating intolerance to truncating or missense variants32. We intersected these lists to 765 
nominate genes that did not display features of DNV-enriched genes in this study. On these 766 
genes we applied ClinGen criteria38 for gene-disease association.  767 
 768 
Data availability  769 
The authors declare that all data used for computing results supporting the findings of this 770 
study are available within the paper and its supplementary information files. Raw sequencing 771 
data of published cohorts are referenced at the respective publications. Raw sequencing data 772 
of cohort EuroEPINOMICS RES have been deposited in the European Genome-phenome 773 
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